Page last updated: 2024-08-26

cp-55,940 and Colitis

cp-55,940 has been researched along with Colitis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andrzejak, V; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; El Bakali, J; Lambert, DM; Leleu-Chavain, N; Lemaire, L; Lemoine, A; Mansouri, R; Millet, R; Muccioli, GG; Renault, N; Rigo, B; Tourteau, A	1

Other Studies

1 other study(ies) available for cp-55,940 and Colitis

Article	Year
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. Bioorganic & medicinal chemistry, 2013, Sep-01, Volume: 21, Issue:17 Topics: Animals; Anti-Inflammatory Agents; Cell Proliferation; Colitis; Dextran Sulfate; HT29 Cells; Humans; Interleukin-1beta; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Tumor Necrosis Factor-alpha	2013

Article

Year

3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.

Bioorganic & medicinal chemistry, 2013, Sep-01, Volume: 21, Issue:17

Topics: Animals; Anti-Inflammatory Agents; Cell Proliferation; Colitis; Dextran Sulfate; HT29 Cells; Humans; Interleukin-1beta; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Tumor Necrosis Factor-alpha

2013